219 related articles for article (PubMed ID: 15491809)
1. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome.
Maeda N; Takeuchi Y; Takada M; Sadzuka Y; Namba Y; Oku N
J Control Release; 2004 Nov; 100(1):41-52. PubMed ID: 15491809
[TBL] [Abstract][Full Text] [Related]
2. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin.
Shimizu K; Asai T; Fuse C; Sadzuka Y; Sonobe T; Ogino K; Taki T; Tanaka T; Oku N
Int J Pharm; 2005 May; 296(1-2):133-41. PubMed ID: 15885465
[TBL] [Abstract][Full Text] [Related]
3. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes.
Katanasaka Y; Ida T; Asai T; Maeda N; Oku N
Int J Pharm; 2008 Aug; 360(1-2):219-24. PubMed ID: 18565703
[TBL] [Abstract][Full Text] [Related]
4. Effective tumor regression by anti-neovascular therapy in hypovascular orthotopic pancreatic tumor model.
Yonezawa S; Asai T; Oku N
J Control Release; 2007 Apr; 118(3):303-9. PubMed ID: 17275944
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic photodynamic therapy with targeted liposomes.
Oku N; Ishii T
Methods Enzymol; 2009; 465():313-30. PubMed ID: 19913174
[TBL] [Abstract][Full Text] [Related]
6. Angiogenic vessel-targeting DDS by liposomalized oligopeptides.
Asai T; Oku N
Methods Mol Biol; 2010; 605():335-47. PubMed ID: 20072892
[TBL] [Abstract][Full Text] [Related]
7. Anti-neovascular therapy using novel peptides homing to angiogenic vessels.
Oku N; Asai T; Watanabe K; Kuromi K; Nagatsuka M; Kurohane K; Kikkawa H; Ogino K; Tanaka M; Ishikawa D; Tsukada H; Momose M; Nakayama J; Taki T
Oncogene; 2002 Apr; 21(17):2662-9. PubMed ID: 11965539
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of angiogenesis-targeted peptide and hydrophobized polyethylene glycol conjugate.
Maeda N; Takeuchi Y; Takada M; Namba Y; Oku N
Bioorg Med Chem Lett; 2004 Feb; 14(4):1015-7. PubMed ID: 15013013
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model.
Abu Lila AS; Kizuki S; Doi Y; Suzuki T; Ishida T; Kiwada H
J Control Release; 2009 Jul; 137(1):8-14. PubMed ID: 19285528
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416.
Katanasaka Y; Ida T; Asai T; Shimizu K; Koizumi F; Maeda N; Baba K; Oku N
Cancer Lett; 2008 Nov; 270(2):260-8. PubMed ID: 18555591
[TBL] [Abstract][Full Text] [Related]
11. Anti-angiogenic inhibition of tumor growth by systemic delivery of PEI-g-PEG-RGD/pCMV-sFlt-1 complexes in tumor-bearing mice.
Kim WJ; Yockman JW; Jeong JH; Christensen LV; Lee M; Kim YH; Kim SW
J Control Release; 2006 Sep; 114(3):381-8. PubMed ID: 16884805
[TBL] [Abstract][Full Text] [Related]
12. Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
Hatakeyama H; Akita H; Ishida E; Hashimoto K; Kobayashi H; Aoki T; Yasuda J; Obata K; Kikuchi H; Ishida T; Kiwada H; Harashima H
Int J Pharm; 2007 Sep; 342(1-2):194-200. PubMed ID: 17583453
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs.
Maeda N; Miyazawa S; Shimizu K; Asai T; Yonezawa S; Kitazawa S; Namba Y; Tsukada H; Oku N
Biol Pharm Bull; 2006 Sep; 29(9):1936-40. PubMed ID: 16946513
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic photodynamic therapy (PDT) by using long-circulating liposomes modified with peptide specific to angiogenic vessels.
Ichikawa K; Hikita T; Maeda N; Yonezawa S; Takeuchi Y; Asai T; Namba Y; Oku N
Biochim Biophys Acta; 2005 May; 1669(1):69-74. PubMed ID: 15843001
[TBL] [Abstract][Full Text] [Related]
15. Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499.
Ando H; Asai T; Koide H; Okamoto A; Maeda N; Tomita K; Dewa T; Minamino T; Oku N
J Control Release; 2014 May; 181():32-9. PubMed ID: 24593893
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model.
Abu-Lila A; Suzuki T; Doi Y; Ishida T; Kiwada H
J Control Release; 2009 Feb; 134(1):18-25. PubMed ID: 19010364
[TBL] [Abstract][Full Text] [Related]
17. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; CichoĊ T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
18. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC.
Asai T; Miyazawa S; Maeda N; Hatanaka K; Katanasaka Y; Shimizu K; Shuto S; Oku N
Cancer Sci; 2008 May; 99(5):1029-33. PubMed ID: 18294280
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?
Hong RL; Huang CJ; Tseng YL; Pang VF; Chen ST; Liu JJ; Chang FH
Clin Cancer Res; 1999 Nov; 5(11):3645-52. PubMed ID: 10589782
[TBL] [Abstract][Full Text] [Related]
20. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors.
Ogawara K; Un K; Minato K; Tanaka K; Higaki K; Kimura T
Int J Pharm; 2008 Jul; 359(1-2):234-40. PubMed ID: 18448289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
